Achillion Pharmaceuticals, Inc.'s Uridine-Analog Nucleotide Prodrug, ACH-3422, Shows Compelling Preclinical Profile
Published: Nov 04, 2013
NEW HAVEN, Conn., Nov. 2, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced a poster presentation detailing the preclinical profile of ACH-3422, a uridine-analog nucleotide prodrug being advanced for the potential treatment of chronic hepatitis C viral infection (HCV). The poster is being presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2013) in Washington D.C.
Help employers find you! Check out all the jobs and post your resume.